跳至主要内容
临床试验/NCT01615653
NCT01615653已完成不适用

Prospective Randomized Trial of EUS Guided Celiac Ganglia Neurolysis (CGN) Versus EUS Guided Celiac Plexus Neurolysis (CPN) for Pancreatic Cancer Pain

Mayo Clinic2 个研究点 分布在 1 个国家目标入组 110 人开始时间: 2009年9月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
Mayo Clinic
入组人数
110
试验地点
2
主要终点
Pain assessed using a numerical rating scale (NRS) from 0 to 10.

研究概览

简要总结

  • Hypothesis:
  • Direct CGN enhances neurolytic drug delivery into celiac ganglia and increases the efficacy of neurolysis and subsequent pain control and survival in patients with pancreatic carcinoma.
  • Rationale:

  • Standard CPN leads to inaccurate delivery of the injectate with rapid dispersal thereby only briefly remaining in contact with neural structures and limiting the degree of neurolysis. Poor targeting and delivery of a neurolytic agent may result in diminished neurolysis and decrease efficacy.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Outcomes Assessor)

入排标准

性别
All
接受健康志愿者

入选标准

  • Unresectable pancreatic carcinoma (T4 or M1) or advanced T3 disease
  • Cytologic or histologic confirmation of pancreatic carcinoma
  • Abdominal pain (≥ 3 on NRS scale), ≥ 2 days/week, lasting ≥ 1 hour/ day, stable intensity for ≥ 7 days
  • EUS clinically indicated (for non-study purposes)

排除标准

  • Uncorrectable coagulopathy: (INR) > 1.5 and/or platelets < 50,000
  • Abdominal surgery within 1 month
  • Prior celiac plexus or ganglia neurolysis.
  • Initiation or modification in chemotherapy or radiotherapy within prior 7 days.
  • Direct tumor infiltration of the celiac trunk and/or celiac ganglia.

结局指标

主要结局

Pain assessed using a numerical rating scale (NRS) from 0 to 10.

时间窗: Baseline to 6 months

pain response will be measured

次要结局

未报告次要终点

研究者

发起方
Mayo Clinic
申办方类型
Other
责任方
Principal Investigator
主要研究者

Michael Levy

Professor of Medicine

Mayo Clinic

研究点 (2)

Loading locations...

相似试验